focus -WSS

focus

author：knowledge 2025-09-06 03:52:58 - browse：26

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： FTC falls short on scrutinizing hospital mergers, study says

Wikipedia

WSS

Medical bills so high, Medicare adding extra digits to claim forms

Harvard scientists, with Google, unveil the most detailed brain map ever

UnitedHealth financials solid despite Change Healthcare cyberattack

Medical bills so high, Medicare adding extra digits to claim forms

Melinda French Gates resigns from Gates Foundation

First Opinion on colorectal cancer screening: letter and response

focus

focus

knowledge

New air purifier tech could be key to improving indoor air quality

Bird flu in milk supply is likely coming from asymptomatic cows

Affirmative action in medical school literally saved lives

Q&A: Jennifer Adair on making gene therapy available globally

Wildfire smoke exposes gaps in outdoor worker protections

Young boy dies in trial for Pfizer Duchenne gene therapy

How to save PrEP access — and even expand it

Drug companies' payments and gifts affect physicians' prescribing

Apple is now the first public company to be valued at $3 trillion

Scientists uncover potential path to treating deadly childhood tumor

focus

Harvard scientists, with Google, unveil the most detailed brain map ever

Covid silver lining: Unprecedented look at human immune system

Element Biosciences CEO lays out genome sequencing strategy

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Scientific mystery highlights the blind spots in genomics databases

Getting Alzheimer's drug Leqembi to patients can be a challenge

hotspot

hotspot

Wikipedia

leisure time